Iovance's Amtagvi® ( lifileucel ) Receives Health Canada Approval for Advanced Melanoma - Iovance Biotherapeutics ( NASDAQ:IOVA )
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
Iovance's Amtagvi® ( lifileucel ) Receives Health Canada Approval for Advanced Melanoma
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy ...
3 Stocks That Could Turn $1,000 Into $5,000 by 2030
All three of these companies are entering a period of what could produce unparalleled top- and bottom-line growth.
Why Iovance Biotherapeutics Stock Plummeted Today
The company's top line nearly doubled.
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.
Pinterest Posts Downbeat Q2 Earnings, Joins Twilio, Trade Desk And Other Big Stocks Moving Lower In Friday Pre-Market Session - Gray Media ( NYSE:GTN ) , Firefly Aerospace ( NASDAQ:FLY )
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Friday. Shares of Pinterest, Inc. PINS fell sharply in pre-market trading after the company reported worse-than-expected second-quarter adjusted EPS results.
Why Expedia Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Click Holdings ( NASDAQ:CLIK ) , BioVie ( NASDAQ:BIVI )
Shares of Expedia Group, Inc. EXPE rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates. Expedia reported second-quarter revenue of $3.79 billion, up 6% year-over-year.
Iovance Biotherapeutics ( IOVA ) Reports Q2 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Iovance ( IOVA ) Q2 Revenue Jumps 93%
Iovance Biotherapeutics ( NASDAQ:IOVA ) , a biotechnology company specializing in cell therapies for solid tumors, reported GAAP earnings on August 7, 2025. The standout news was a 93% year-over-year GAAP revenue growth compared to Q2 2024, driven by its Amtagvi T cell therapy, but both GAAP ...
MaxCyte, Inc. ( MXCT ) Reports Q2 Loss, Misses Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics ( HALO ) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Is Iovance Biotherapeutics Stock Due for a Big Rally?
The biotech stock has been picking up steam of late -- but will it last?
This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?
Even the average price estimate for this stock suggests it can soar, but not everyone's convinced.
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Arrowhead Pharma ( NASDAQ:ARWR ) , Abivax ( NASDAQ:ABVX )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of GE Vernova Inc. GEV rose sharply during Wednesday's session after the company posted better-than-expected second-quarter 2025 earnings and raised its full-year guidance.
This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside
Investing in penny stocks -- companies with share prices under around $5 apiece -- could lead to monster returns over the long run. The flip side is that these corporations tend to carry above-average risk. It's challenging to determine which penny stocks might go on to deliver excellent ...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 ( c ) ( 4 )
SAN CARLOS, Calif., July 18, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) ( "Iovance" or the "Company" ) , a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( "TIL" ) therapies for patients with ...
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Iovance Biotherapeutics ( NASDAQ:IOVA )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance ( IOVA ) To Contact Him Directly To Discuss Their Options
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Blue Gold ( NASDAQ:BGL ) , FB Financial ( NYSE:FBK )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Tuesday. Shares of Simulations Plus, Inc SLP fell sharply in pre-market trading after the company reported downbeat third-quarter sales and cut its FY2025 EPS guidance.
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN CARLOS, Calif., July 15, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
SAN CARLOS, Calif., July 15, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) , a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( TIL ) therapies for patients with cancer, today announced ...
Levi & Korsinsky Reminds Iovance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 14, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ( "Iovance" or the "Company" ) IOVA of a class action securities lawsuit.
IOVA FINAL DEADLINE ALERT: Hagens Berman Alerts Iovance ( IOVA ) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN FRANCISCO, July 14, 2025 ( GLOBE NEWSWIRE ) -- firm Iovance Biotherapeutics Inc. IOVA announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025.
FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors in Iovance Biotheapeutics, Inc. ( IOVA ) to Inquire About Their Rights in Class Action Lawsuit - Iovance Biotherapeutics ( NASDAQ:IOVA )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance ( IOVA ) To Contact Him Directly To Discuss Their Options
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma - Iovance Biotherapeutics ( NASDAQ:IOVA )
61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm - Iovance Biotherapeutics ( NASDAQ:IOVA )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance ( IOVA ) To Contact Him Directly To Discuss Their Options
IOVA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 14 Deadline in Securities Class Action - IOVA - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 12, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. IOVA between May 9, 2024 and May 8, 2025, both dates inclusive ( the "Class Period" ) , of the important July 14, 2025 lead ...
IOVA 2-DAY DEADLINE ALERT: Iovance's ( IOVA ) CFO Resigns Amid Launch Setbacks and Securities Class Action- Hagens Berman - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN FRANCISCO, July 12, 2025 ( GLOBE NEWSWIRE ) -- Biotechnology firm Iovance Biotherapeutics Inc. IOVA announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025.
IOVA FRAUD ALERT: Iovance Biotherapeutics 44% Stock Drop Triggers Securities Fraud Class Action - Investors Notified to Contact BFA Law by July 14 ( NASDAQ:IOVA ) - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 12, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. IOVA and certain of the Company's senior executives for potential violations of the federal securities laws.
Investors who lost money on Iovance Biotherapeutics, Inc. ( IOVA ) should contact The Gross Law Firm about pending Class Action - IOVA - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 10, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. IOVA. Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...
IOVA 4-DAY DEADLINE ALERT: Iovance's ( IOVA ) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit - Hagens Berman - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN FRANCISCO, July 10, 2025 ( GLOBE NEWSWIRE ) -- Biotechnology firm Iovance Biotherapeutics Inc. IOVA announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025.
IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud - Contact BFA Law by the July 14 Legal Deadline ( NASDAQ:IOVA ) - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 10, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. IOVA and certain of the Company's senior executives for potential violations of the federal securities laws.
Iovance Biotherapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. July 14, 2025 Deadline to file Lead Plaintiff Motion - Iovance Biotherapeutics ( NASDAQ:IOVA )
Investors can contact the law firm at no cost to learn more about recovering their losses
IOVA DEADLINE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 14 Deadline in Securities Class Action - IOVA - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 09, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. IOVA between May 9, 2024 and May 8, 2025, both dates inclusive ( the "Class Period" ) , of the important July 14, 2025 lead ...
IOVA 6-DAY DEADLINE ALERT: Iovance's ( IOVA ) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit - Hagens Berman - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN FRANCISCO, July 08, 2025 ( GLOBE NEWSWIRE ) -- Biotechnology firm Iovance Biotherapeutics Inc. IOVA announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025.
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 08, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ( "Iovance" or the "Company" ) IOVA of a class action securities lawsuit.
IOVA NOTICE: Iovance Biotherapeutics Shareholders are Notified of the Pending Class Action Lawsuit -- Contact BFA Law by July 14 Court Deadline ( NASDAQ:IOVA ) - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 08, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. IOVA and certain of the Company's senior executives for potential violations of the federal securities laws.
Shareholders that lost money on Iovance Biotherapeutics, Inc. ( IOVA ) Urged to Join Class Action - Contact The Gross Law Firm to Learn More - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 07, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. IOVA. Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...
IOVA 8-DAY DEADLINE ALERT: Iovance's ( IOVA ) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit - Hagens Berman - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN FRANCISCO, July 06, 2025 ( GLOBE NEWSWIRE ) -- Biotechnology firm Iovance Biotherapeutics Inc. IOVA announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025.
IOVA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class...
New York, New York-- ( Newsfile Corp. - July 6, 2025 ) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) between May 9, 2024 and May 8, 2025, both dates inclusive ( the "Class Period" ) , of the important ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - Iovance Biotherapeutics ( NASDAQ:IOVA )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options
IOVA SHAREHOLDER ALERT: Suffer Losses on Iovance Biotherapeutics? Contact BFA Law by July 14 Securities Fraud Class Action Deadline ( NASDAQ:IOVA ) - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 06, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. IOVA and certain of the Company's senior executives for potential violations of the federal securities laws.
Is This Beaten-Down Stock a Millionaire Maker?
Over the past two years, Iovance Biotherapeutics ( NASDAQ: IOVA ) , a small-cap biotech company, has made significant clinical and regulatory progress. However, the stock has also plunged over this period -- shares are currently trading for less than $2 apiece.
IOVA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - IOVA - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 05, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. IOVA between May 9, 2024 and May 8, 2025, both dates inclusive ( the "Class Period" ) , of the important July 14, 2025 lead ...
Faruqi & Faruqi Reminds Iovance Biotherapeutics of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA
Faruqi & Faruqi Reminds Iovance Biotherapeutics of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July ...
IOVA SHAREHOLDERS: The Iovance Biotherapeutics July 14 Class Action Deadline is Approaching -- Contact BFA Law if You Suffered Losses ( NASDAQ:IOVA ) - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 04, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. IOVA and certain of the Company's senior executives for potential violations of the federal securities laws.
Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 03, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ( "Iovance" or the "Company" ) IOVA of a class action securities lawsuit.
IOVA CLASS ACTION: A Class Action was filed against Iovance Biotherapeutics for Securities Fraud -- Contact BFA Law by July 14 Legal Deadline ( NASDAQ:IOVA ) - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, July 02, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. IOVA and certain of the Company's senior executives for potential violations of the federal securities laws.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the Firm - Iovance Biotherapeutics ( NASDAQ:IOVA ) , Krispy Kreme ( NASDAQ:DNUT )
NEW YORK, June 30, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Krispy Kreme, Inc. DNUT, Strategy Incorporated MSTR, Organon & Co. OGN, and Iovance ...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Biotherapeutics, Inc. Lawsuit - IOVA - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, June 30, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ( "Iovance" or the "Company" ) IOVA of a class action securities lawsuit.
IOVA IMPORTANT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - IOVA - Iovance Biotherapeutics ( NASDAQ:IOVA )
NEW YORK, June 29, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. IOVA between May 9, 2024 and May 8, 2025, both dates inclusive ( the "Class Period" ) , of the important July 14, 2025 lead ...
